Onxeo receives a new patent in the United States for Livatag® in the treatment of squamous cell carcinoma hey…

This patent granted by the USPTO* is relative to the route of administration, specific of Livatag® and extends the protection of the claims associated until 2032

Download the free guide
Boost your gains

Paris (France), may 10, 2017 – 18: 30 CEST – Onxeo SA (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, especially in oncology, announced today that it has received a notice of acceptance by the patent Office and trademark United States (USPTO), the patent application covering the route of administration, specific of Livatag®, currently being evaluated in a phase III clinical trial (ReLive) in the second line treatment of hepatocellular carcinoma (primary liver cancer).

Livatag® (doxorubicin Transdrug™) is based on an innovative technology for formulation of doxorubicin (a chemotherapeutic agent) in the form of nanoparticles made of polyalkylcyanoacrylate, cyclodextrin, and poloxamer. This formulation is in the form of nanoparticles confers novel properties and promising, including the ability to overcome the mechanisms of chemoresistance developed by tumor cells may affect the efficiency of the chemotherapy agents.

“The United States is a target market important for Livatag®. This new patent in the United States, strengthens considerably our portfolio of intellectual property for Livatag® and increases the value of this candidate who is at an advanced stage of clinical development. We look forward to the availability of data from our trial ReLive planned in the middle of the year”, declares Judith Greciet, CEO of Onxeo.

This new patent provides protection for claims related to the United States until 2032, and is in addition to the patents previously granted for this same family for other major territories such as Europe and Japan. A family of additional patents have also been filed on the basis of a specific composition of the nanoparticles Livatag®, which, if granted, would extend the protection of Livatag® until 2036.

* USPTO : U.s. Patent and Trademark Office – Office of patent and trademark United States

About Onxeo

Onxeo is a company of biotechnology with the clinical stage, specializing in the development of innovative medicines for the treatment of orphan diseases in particular in the field of oncology, in response to a strong demand therapy in one of the segments with the strongest growth of the pharmaceutical industry.
Onxeo has the ambition of becoming a global leader and a pioneer in the field of cancer is an orphan, or rare. The strategy of Onxeo is based on the development of therapies for advanced, effective and safe, designed to improve the lives of patients with rare cancers or resistant to making a true difference compared to current therapies.
The portfolio of Onxeo in cancers orphans includes 3 major products in a number of programs in preclinical and clinical courses, alone or in combination for multiple indications of cancer.
The Company is based in Paris, France, with offices in Copenhagen and New York, and has approximately 60 employees. Onxeo is listed on Euronext Paris, France (Mnémo : ONXEO, ISIN Code : FR0010095596) and Nasdaq Copenhagen, Denmark (Mnémo : ONXEO).
For more information : www.onxeo.com

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply